Are you offering chemotherapy for premenopausal patients with HR+ node-positive breast CA with OncoType dx scores in the intermediate range of 11-25?  

This is a great question. Yes, I typically recommend adjuvant chemotherapy in premenopausal women with early stage HR+ breast cancer with nodal involvement regardless of Oncotype DX RS. I do not send an Oncotype DX score in this setting due to the modest benefit of chemotherapy seen in premenopausal...

The RxPONDER trial was conducted to definitively answer the question of whether Recurrence Score (RS) could be used to predict which women with HR+, HER-, node-positive breast cancer would benefit from chemotherapy. 5,083 women with this cancer and with an RS of 25 or less, were randomly assigned to...

What is the estimated benefit of chemotherapy in genomic low-risk RS for premenopausal patients? Would you consider or offer ovarian suppression as an alternative to chemotherapy, since possibly the most benefit of chemo for this patient population might be derived from ovarian suppression as a side...